DV supervised the writing
Here's How to Break Through - REJUV, accessed April 23, 2025, Wegovy timeline: what to expect - Numan, accessed April 23, 2025, Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes, accessed April 23, 2025, Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and MetaAnalysis of Direct Comparative Studies - PubMed Central, accessed April 23, 2025, SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial, accessed April 23, 2025, Lilly's tirzepatide superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs
Such reactions are generally mild, self-limiting, and resolve within a few days without specific intervention
All patients in the trial initiated treatment with a 0.25 mg dose of semaglutide that was doubled every 4 weeks until the target dose was achieved
However, this will warrant a discussion with their provider to determine if this is the best course of action